EFFICACY AND SAFETY OF ORIGINAL DRUG BASED ON HEXAPEPTIDE SUCCINATE IN COMPLEX COVID-19 THERAPY IN ADULTS HOSPITALIZED PATIENTS

Currently, there are data that that make it possible to speak about a high clinical efficacy of the use of succinic salt of tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine (hexapeptide succinate) for the COVID-19 treatment. This article is devoted to the results of clinical trials of the original Russian drug based on it.

The aim of the study was to evaluate a clinical efficacy, safety and tolerability of intramuscular and inhalation use of hexapeptide succinate in complex therapy in comparison with standard therapy in patients with moderate COVID-19.

Materials and methods. The research was conducted from February 28, 2022 to November 22, 2022 based on 10 research centers in the Russian Federation. The study included hospitalized patients (n=312) over 18 years of age with moderate COVID-19 who had undergone a screening procedure and were randomized into 3 groups: group 1 received standard therapy in accordance with the Interim Guidelines in force at the time of the study, within 10 days; group 2 received hexapeptide succinate (Ambervin® Pulmo) intramuscularly at the dose of 1 mg once a day for 10 days; group 3 received hexapeptide succinate (Ambervin® Pulmo) 10 mg once a day by inhalation for 10 days.

Results. According to the results of the study, therapy with the drug hexapeptide succinate, both intramuscular and inhaled, provided an acceleration of recovery up to the complete absence of the disease signs in more than 80% of hospitalized COVID-19 patients. By the end of the therapy course with the drug, more than 60% of patients had met the criteria for discharge from hospital and could continue the treatment on an outpatient basis. About 70% of patients in the inhalation group and 80% in the intramuscular hexapeptide succinate injection group had concomitant diseases (hypertension – 28%, obesity – 14%), which indicates the effectiveness of this drug use in comorbid patients. The use of the drug contributed to the restoration of damaged lung tissues, normalization of oxygenation, the disappearance of shortness of breath and a decrease in the duration of the disease symptoms compared with standard therapy. As a result of a comparative analysis of adverse events in terms of their presence, severity, causal relationship with the therapy and outcome, there were no statistically significant differences between the treatment groups.

Conclusion. Thus, the results of the clinical study of the succinate hexapeptide efficacy and safety showed the feasibility of using the drug in pathogenetic therapy COVID-19 regimens.

1. Bulgakov S.A. The use of agonists of opioid peptide receptors in the gastroenterological practice. Russian Journal of Evidence-Based Gastroenterology. 2015;4(1):14–8. DOI:10.17116/dokgastro201541-214-18. Russian

2. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975 Dec 18;258(5536):577–80. DOI:10.1038/258577a0

3. Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc Natl Acad Sci U S A. 1971 Aug;68(8):1742–7. DOI:10.1073/pnas.68.8.1742

4. Petrocelli G, Pampanella L, Abruzzo PM, Ventura C, Canaider S, Facchin F. Endogenous Opioids and Their Role in Stem Cell Biology and Tissue Rescue. Int J Mol Sci. 2022 Mar 30;23(7):3819. DOI:10.3390/ijms23073819

5. Fricker LD, Margolis EB, Gomes I, Devi LA. Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions. Mol Pharmacol. 2020 Aug;98(2):96–108. DOI:10.1124/mol.120.119388

6. Kibaly C, Xu C, Cahill CM, Evans CJ, Law PY. Non-nociceptive roles of opioids in the CNS: opioids’ effects on neurogenesis, learning, memory and affect. Nat Rev Neurosci. 2019 Jan;20(1):5–18. DOI:10.1038/s41583-018-0092-2

7. Eisenstein TK. The Role of Opioid Receptors in Immune System Function. Front Immunol. 2019 Dec 20;10:2904. DOI:10.3389/fimmu.2019.02904

8. Bulgakov S.A. Hexapeptide dalargin in clinical gastroenterology: 30 years’ of clinical application of the drug. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):103–12. DOI:10.22416/1382-4376-2016-26-3-103-112. Russian

9. Shloznikov BM, Likhvantsev VV, Kuznetsov AIu, Peretrukhin AI, Tverskoĭ AL, Machulin AV, Grin’ko AN. Dalargin – osnovnoe sredstvo intraoperatsionnoĭ zashchity bol’nogo pri korrektsii defekta mezhpredserdnoĭ peregorodki v usloviiakh iskusstvennogo krovoobrashcheniia: novy metod anestezii [Dalargin – a basic means of intraoperative protection of a patient during correction of an atrial septal defect under conditions of artificial circulation: a new method of anesthesia]. Anesteziol Reanimatol. 1989 Jul-Aug;(4):21–5. Russian

10. Likhvantsev VV, Smirnova VI, Kuznetsov AIu, Peretrukhin AI,Kakurin FF, Grin’ko AN. Sravnitelńye aspekty primeneniia dalargina v komplekse anesteziologicheskoĭ zashchity pri khirurgicheskoĭ korrektsii vrozhdennykh porokov serdtsa [Comparative aspects of the use of dalargin in comprehensive anesthesiologic protection during the surgical correction of congenital heart disease]. Anesteziol Reanimatol. 1993 Jul-Aug;(4):23–8. Russian

11. Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun. 2006 Jan;20(1):9–14. DOI:10.1016/j.bbi.2005.02.002

12. Gein S.V. Opioidergic regulation of immune reactions. Molecular medicine. 2010; 4: 17–21. Russian

13. Franchi S, Moretti S, Castelli M, Lattuada D, Scavullo C, Panerai AE, Sacerdote P. Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav Immun. 2012 Mar;26(3):480–8. DOI:10.1016/j.bbi.2011.12.010

14. Brejchova J, Holan V, Svoboda P. Expression of Opioid Receptors in Cells of the Immune System. Int J Mol Sci. 2020 Dec 30;22(1):315. DOI:10.3390/ijms22010315

15. Zabrodin ON. To the noradrenergic component of the mechanisms of stress-limiting and healing effects of dalargin. Reviews on Clinical Pharmacology and Drug Therapy, 2016;14(4):61–6. DOI: 10.17816/RCF14461-66

16. Yasenyavskaya AL, Samotrueva MA, Bashkina OA, Andreeva LA, Myasoedov NF, Tyurenkov IN, Karaulov AV. Neuropeptide regulation of immunity. Immunologiya. 2018; 39(5-6): 326–36. DOI:10.18821/0206-4952-2018-39-5-6-326-336

17. Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020 Sep;10(9):200160. DOI:10.1098/rsob.200160

18. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020 Jun;80(6):607–13. DOI:10.1016/j.jinf.2020.03.037

19. Chen R, Lan Z, Ye J, Pang L, Liu Y, Wu W, Qin X, Guo Y, Zhang P. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front Immunol. 2021 Apr 28;12:589095. DOI:10.3389/fimmu.2021.589095

20. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033–4. DOI:10.1016/S0140-6736(20)30628-0

21. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017 Nov 9;377(19):1904–5. DOI:10.1056/NEJMc1711824

22. Petrov VI, Amosov AA, Gerasimenko AS, Shatalova OV, Ponomareva AV, Akinchits AN, Kulakova IS, Gorbatenko VS. Mechanisms of cytokine storm development in COVID-19 and new potential targets of pharmacotherapy. Pharmacy & Pharmacology. 2020;8(6):380-391. DOI:10.19163/2307-9266-2020-8-6-380-391

23. Zemskov DN, Balykova LA, Radaeva OA, Zaslavskaya KY, Bely PA, Semenova EV, Shirmankina MV, Koryanova KN. Current aspects of etiotropic COVID-19 therapy. Pharmacy & Pharmacology. 2022;10(5):432–45. DOI:10.19163/2307-9266-2022-10-5-432-445

24. Parakhonsky AP. Regulation of the immune response by opioid peptides. Advances in current natural sciences. 2008;(10):77–8. Russian

25. Scientific Center for Biomedical Technologies of the Federal Medical and Biological Agency; Vinogradov VA, Skvortsova VI, Karkishchenko VN, et al. Using dalargin for producing agents for treating covid-19 coronavirus infection. Patent No. 2728939 C1 Russian Federation. 2020 March 03.

26. Ukrainskaya LA, Vasilieva LS. Limitation stress-induced light alteration by activating stress-limiting systems. Siberian Medical Journal (Irkutsk). 2002;31(2):28–9. Russian

27. Balachevsky BV, Kurzanov AN, Slavinsky AA. Dalargin-induced modulation of the functional and metabolic activity of neutrophilic leukocytes. Advances in current natural sciences. 2008;(5):75–7. Russian